Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Objectives: To estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. Methods: We conducted a matched case-control study among all individuals eligible for sot...

Full description

Bibliographic Details
Main Authors: Ahmed Zaqout, Muna A. Almaslamani, Hiam Chemaitelly, Samar A. Hashim, Ajithkumar Ittaman, Abeir Alimam, Fatma Rustom, Joanne Daghfal, Mohammed Abukhattab, Sawsan AlMukdad, Anvar Hassan Kaleeckal, Ali Nizar Latif, Adeel A. Butt, Roberto Bertollini, Abdullatif Al-Khal, Ali S. Omrani, Laith J. Abu-Raddad
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
Sotrovimab
Omicron
BA.2
Epidemiology
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222005227

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222005227

Similar Items